Drugs / S-600918
S-600918
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04110054 | Feb → Dec 2020 | — | Shionogi | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06776432 Comparator | Apr 2025 → Dec 2026 expected | sleep apnea syndrome | Shionogi | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | S-600918 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04110054 ↗ |
| Known as | (E/Z)-S-600918 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5084939 ↗ |
| Known as | (E/Z)-SIVOPIXANT | ChEMBL registry synonym — accepted as the source's own label CHEMBL5084939 ↗ |
| Known as | Sivopixant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06776432 ↗ |
| Action | Inhibit | “P2X3 receptor antagonist” PMID 36512069 ↗ Dec 2022 |
| Route | Oral | “Participants will receive 50 mg S-600918 orally once a day for 28 days.” NCT04110054 ↗ |